Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
Latest Information Update: 26 Sep 2024
Price :
$35 *
At a glance
- Drugs Inaticabtagene autoleucel (Primary) ; Cyclophosphamide; Fludarabine
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors Juventas Cell Therapy
- 18 Sep 2024 Planned primary completion date changed from 30 Jun 2024 to 30 Dec 2024.
- 04 Mar 2024 Planned primary completion date changed from 30 Dec 2023 to 30 Jun 2024.
- 18 Sep 2023 Planned number of patients changed from 36 to 60.